Bray F, Laversanne M, Sung H, Me JF, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022. https://doi.org/10.3322/caac.21834.

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.

CAS  PubMed  PubMed Central  Google Scholar 

Sangro B, Gomez-Martin C, De La Mata M, Iñarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59:81–88.

CAS  PubMed  Google Scholar 

Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child–Pugh class B cirrhosis: safety and clinical outcomes in a retrospective case series. Cancer. 2019;125:3234–41.

CAS  Google Scholar 

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017;5:44.

PubMed  PubMed Central  Google Scholar 

Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222–32.

CAS  PubMed  Google Scholar 

Zhu G-Q, Tang Z, Huang R, Qu W-F, Fang Y, Yang R, et al. CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023;9:25.

CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Zhu L, Liang C, Huang X, Liu Z, Huo J, et al. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis. J Hepatol. 2023;79:1185–1200.

CAS  PubMed  Google Scholar 

Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, et al. Tumor-associated macrophages produce interleukin 6 and sSignal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology. 2014;147:1393–404.

CAS  PubMed  Google Scholar 

Dhanasekaran R, Venkatesh SK, Torbenson M, Roberts LR. Clinical implications of basic research in hepatocellular carcinoma. J Hepatol. 2017. https://doi.org/10.1016/j.jhep.2015.09.008.

Lai Q, Vitale A, Manzia T, Foschi F, Levi Sandri G, Gambato M, et al. Platelets and hepatocellular cancer: bridging the bench to the clinics. Cancers. 2019;11:1568.

CAS  PubMed  PubMed Central  Google Scholar 

Dong S, Guo X, Han F, He Z, Wang Y. Emerging role of natural products in cancer immunotherapy. Acta Pharm Sin B. 2022;12:1163–85.

CAS  PubMed  Google Scholar 

Wei C-Y, Zhu M-X, Zhang P-F, Huang X-Y, Wan J-K, Yao X-Z, et al. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol. 2022;77:163–76.

CAS  PubMed  Google Scholar 

Lu J-C, Zhang P-F, Huang X-Y, Guo X-J, Gao C, Zeng H-Y, et al. Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. J Hematol Onco. 2021;14:200.

CAS  Google Scholar 

Cheng K, Cai N, Zhu J, Yang X, Liang H, Zhang W. Tumor-associated macrophages in liver cancer: From mechanisms to therapy. Cancer Commun. 2022;42:1112–40.

Google Scholar 

Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78:770–82.

CAS  PubMed  Google Scholar 

Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S, et al. TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 2023;79:126–40.

CAS  PubMed  Google Scholar 

He H, Chen S, Fan Z, Dong Y, Wang Y, Li S, et al. Multi-dimensional single-cell characterization revealed suppressive immune microenvironment in AFP-positive hepatocellular carcinoma. Cell Discov. 2023;9:60.

CAS  PubMed  PubMed Central  Google Scholar 

Lu J-C, Wu L-L, Sun Y-N, Huang X-Y, Gao C, Guo X-J, et al. Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma. Nat Commun. 2024;15:621.

CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Lu R, Abuduhailili X, Feng Y. Apolipoprotein E: a potential prognostic and diagnostic biomarker for hepatocellular carcinoma. J Hepatocell Carcinoma. 2025;12:301–24.

PubMed  PubMed Central  Google Scholar 

Wang Y, Zhu G-Q, Yang R, Wang C, Qu W-F, Chu T-H, et al. Deciphering intratumoral heterogeneity of hepatocellular carcinoma with microvascular invasion with radiogenomic analysis. J Transl Med. 2023;21:734.

CAS  PubMed  PubMed Central  Google Scholar 

Wan S, He Q-Y, Yang Y, Liu F, Zhang X, Guo X, et al. SPARC stabilizes ApoE to induce cholesterol-dependent invasion and sorafenib resistance in hepatocellular carcinoma. Cancer Res. 2024;84:1872–88.

CAS  PubMed  Google Scholar 

Yao J, Wu D, Qiu Y. In vitro analyses of paracrine effects of murine classically activated macrophage on beige adipocyte metabolism. STAR Protoc. 2022;3:101480.

CAS  PubMed  PubMed Central  Google Scholar 

Siegert I, Schatz V, Prechtel AT, Steinkasserer A, Bogdan C, Jantsch J. Electroporation of siRNA into mouse bone marrow-derived macrophages and dendritic cells. In: Li S, Cutrera J, Heller R, Teissie J, editors. Electroporation Protocols. 2014. https://doi.org/10.1007/978-1-4614-9632-8_9.

Zhang Q, He Y, Luo N, Patel SJ, Han Y, Gao R, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179:829–845.e20.

CAS  PubMed  Google Scholar 

Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15:104–16.

CAS  PubMed  PubMed Central  Google Scholar 

Xiao J, Wang S, Chen L, Ding X, Dang Y, Han M, et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages. Immunity. 2024;57:1087–1104.e7.

CAS  PubMed  Google Scholar 

Goossens P, Rodriguez-Vita J, Etzerodt A, Masse M, Rastoin O, Gouirand V, et al. Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 2019;29:1376–89.e4.

CAS  PubMed  Google Scholar 

Li T, Li X, Zamani A, Wang W, Lee C-N, Li M, et al. c-Rel is a myeloid checkpoint for cancer immunotherapy. Nat Cancer. 2020;1:507–17.

CAS  PubMed  PubMed Central  Google Scholar 

Klement JD, Redd PS, Lu C, Merting AD, Poschel DB, Yang D, et al. Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment. Cancer Cell. 2023;41:620–36.e9.

CAS  PubMed  PubMed Central  Google Scholar 

Chang Y, Kang P, Cui T, Guo W, Zhang W, Du P, et al. Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo. J Transl Med. 2023;21:434.

CAS  PubMed  PubMed Central  Google Scholar 

Sharma A, Seow JJW, Dutertre C-A, Pai R, Blériot C, Mishra A, et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell. 2020;183:377–94.e21.

CAS  PubMed  Google Scholar 

Li Y, Shen Z, Chai Z, Zhan Y, Zhang Y, Liu Z, et al. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity. Gut. 2023;72:2307–20.

CAS  PubMed  Google Scholar 

Liu C, Xie J, Lin B, Tian W, Wu Y, Xin S, et al. Pan-cancer single-cell and spatial-resolved profiling reveals the immunosuppressive role of APOE+ Macrophages In Immune Checkpoint Inhibitor Therapy. Adv Sci. 2024;11:2401061.

CAS  Google Scholar 

Tharp KM, Kersten K, Maller O, Timblin GA, Stashko C, Canale FP, et al. Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment. Nat Cancer. 2024;5:1045–62.

CAS  PubMed  PubMed Central  Google Scholar 

Khan MN, Mao B, Hu J, Shi M, Wang S, Rehman AU, et al. Tumor-associated macrophages and CD8+ T cells: dual players in the pathogenesis of HBV-related HCC. Front Immunol. 2024;15:1472430.

CAS  PubMed  PubMed Central  Google Scholar 

Ma S, Sun B, Duan S, Han J, Barr T, Zhang J, et al. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells. Nat Immunol. 2023;24:255–66.

CAS  PubMed  PubMed Central  Google Scholar 

Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, et al. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 2019;10:2416.